Animal reproduction studies have failed to demonstrate a risk to the fetus and there are no adequate and well-controlled studies in pregnant women OR Animal studies have shown an adverse effect, but adequate and well-controlled studies in pregnant women have failed to demonstrate a risk to the fetus in any trimester.
Mode of Action
Magnesium sulfate decreases levels of acetylcholine in motor nerve terminals. It also acts on the myocardium by decreasing the rate of SA node impulse formation and prolonging the conduction time.
Adult: IV
Hypomagnesaemia
Symptomatic deficiency: 1-2 g over 5-60 mins, then maintain at 0.5-1 g/hr if needed.
Severe: 1-2 g/hr for 3-6 hr, then 0.5-1 g/hr as needed to correct deficiency.
Torsades de pointes W/ pulses: Loading dose: 1-2 g over 5-60 mins, then maintain at 0.5-1 g/hr as needed.
Pulseless: 1-2 g over 5-20 mins.
Barium poisoning 1-2 g.
Cerebral oedema 2.5 g.
Eclampsia
Loading dose: 4-5 g over 10-15 mins, followed by either a continuous infusion of 1 g/hr or deep IM doses of 4-5 g into alternate buttocks 4 hrly.
If seizure recurs, an additional IV dose of 2-4 g may be given. Not to exceed 30-40 g/24 hr.
IM Hypomagnesaemia Mild deficiency: 1 g 6 hrly for 4 doses.
Severe deficiency: Up to 250 mg/kg w/in 4 hr.
Child Dose
N/A
Renal Dose
N/A
Administration
N/A
Disclaimer
The information provided herein are for informational purposes only and not intended to be a substitute for professional medical advice, diagnosis, or treatment. Please note that this information should not be treated as a replacement for physical medical consultation or advice. Great effort has been placed to provide accurate and comprehensive data. However, Medicart along with its authors and editors make no representations or warranties and specifically disclaim all liability for any medical information provided on the site. The absence of any information and/or warning to any drug shall not be considered and assumed as an implied assurance of the Company.